Cohort of Patients With Chronic Myelomonocytic Leukemia

A prospective, non-interventional study involving the collection of biological samples with associated anonymised data.

Biological samples will be collected at the time of diagnosis and/or as the disease progresses, with or without treatment, always in conjunction with tests scheduled as part of routine care or within the context of a clinical trial.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Leukemia Bone Marrow Diseases Chronic Disease Disease Attributes Hematologic Diseases Hemic and Lymphatic Diseases Leukemia, Myeloid Leukemia, Myelomonocytic, Chronic Myelodysplastic-Myeloproliferative Diseases Myelomonocytic Leukemia, Chronic Neoplasms Neoplasms by Histologic Type Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Amiens Picardie, Amiens, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adults aged 18 years and over
Blood monocytosis ≥ 0.5 × 10⁹/L and ≥ 10% of total white blood cells or
Confirmed diagnosis of chronic myelomonocytic leukemia
Regardless of stage (chronic or transformed), and whether or not currently being treated
Signed informed consent

Exclusion criteria

Active, uncontrolled infection (particularly hepatitis B, hepatitis C, HIV)
Refusal informed consent

Treatment and study plan

Sampling

Biological

Blood samples taken as part of a scheduled assessment within the context of medical care

Standard sample: 2 x 10 mL EDTA tubes
For the initial assessment: 1 x 10 mL dry tube At the request of the research teams: one EDTA tube may be replaced by a heparinised or citrated tube, depending on the planned research. Bone marrow samples, taken during a scheduled myelogram as part of medical care
Myelogram: 1 x 2 mL EDTA tube In exceptional cases, during a scheduled surgical procedure, a tissue sample will be considered in consultation with the surgeon (affected tissue, surrounding healthy tissue).

Primary outcomes

Understanding the pathophysiology of chronic myelomonocytic leukaemia

Time frame: through study completion, an average of 15 years

optimise diagnosis, improve prognostic stratification, identify new treatment options and assess patients' response to proposed treatments through the analysis of blood or bone marrow samples collected as part of routine care or clinical trials

Study contacts

Contact information is provided by the study sponsor or research team.

Christophe WILLEKENS

CONTACT

[email protected]

+33 1 42 11 23 79

Eric SOLARY

CONTACT

[email protected]

+33 1 42 11 67 26

Sponsors and collaborators

Lead sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Other

Registry information

Acronym: MYELOMONO-3

Important dates

Study start: 2026
Primary completion: 2040
Study completion: 2040
First posted: Apr 6, 2026
Registry last updated: May 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting